Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Positive Panel, But What's Ahead For Intercept's Ocaliva?

This article was originally published in Scrip

Executive Summary

After the FDA's glowing review on paper and even more so at the meeting of the agency's Gastrointestinal Drugs Advisory Committee, it was highly likely the panel would back a speedy approval of Intercept Pharmaceuticals Inc.'s Ocaliva (obeticholic acid) as a treatment for primary biliary cholangitis (PBC), a rare and potentially fatal liver disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register